[Large granular lymphocyte leukemia]. 1996

M Mizuki, and S Tagawa, and M Shibano, and T Hirota, and T Machii, and T Kitani, and M Ohsawa, and K Aozasa, and J Nojima
Department of Hematology and Oncology, Osaka University Medical School, Suita.

Large granular lymphocyte leukemia (LGLL) is defined as clonal proliferation of LGLs in peripheral blood. The following studies were conducted to address some issues in chronic LGLL. (1) Chronic LGLL is characterized by the indolent course, and the diagnosis of leukemia is difficult in such patients as those without distinct organomegaly and/or any evidence of monoclonality. We performed immunohistological studies in a patient with persistent NK lymphocytosis. No organomegaly had been seen in the patient during a three-year-observation, who died from cerebrovascular accident. The autopsy findings revealed multi-organ infiltration including spleen, liver, bone marrow, lymph nodes and lung. These findings suggest that the cells of chronic LGLL have infiltrative capacity characteristic of malignant cells. (2) Lymphocytosis in chronic LGLL is usually stable for a long period. We found that both T- and NK-LGLL cells strongly expressed CD95, an apoptosis related protein. Anit-CD95 did not induce apoptosis, but suppressed proliferation induced by IL-2 or anti-CD3. These results suggest that CD95-CD95 ligand system is involved in the slow cell growth characteristic of chronic LGLL. (3) CD4+CD8+ double positive (DP) cases are rarely seen in LGLL, and the physiologic counterpart of the leukemic cells has not been determined yet. We found that the DP-LGLL had alpha alpha type in the CD8 subunit and did not express RAG-1, these findings being characteristic of peripheral T cells. We also found that they expressed IL-4 mRNA and secreted IL-4 on activation. These results strongly suggest that DP-T-LGLL represents an expansion of a rare subset of peripheral DP-T cells, possibly derived from IL-4 activated CD4 single positive T cells.

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D008297 Male Males
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015847 Interleukin-4 A soluble factor produced by activated T-LYMPHOCYTES that induces the expression of MHC CLASS II GENES and FC RECEPTORS on B-LYMPHOCYTES and causes their proliferation and differentiation. It also acts on T-lymphocytes, MAST CELLS, and several other hematopoietic lineage cells. B-Cell Growth Factor-I,B-Cell Stimulatory Factor-1,Binetrakin,IL-4,Mast Cell Growth Factor-2,B Cell Stimulatory Factor-1,B-Cell Growth Factor-1,B-Cell Proliferating Factor,B-Cell Stimulating Factor-1,B-Cell Stimulatory Factor 1,BCGF-1,BSF-1,IL4,MCGF-2,B Cell Growth Factor 1,B Cell Growth Factor I,B Cell Proliferating Factor,B Cell Stimulating Factor 1,B Cell Stimulatory Factor 1,Interleukin 4,Mast Cell Growth Factor 2
D017254 Leukemic Infiltration A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site. Infiltration, Leukemic,Infiltrations, Leukemic,Leukemic Infiltrations
D018414 CD8-Positive T-Lymphocytes A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes. Suppressor T-Lymphocytes, CD8-Positive,T8 Cells,T8 Lymphocytes,CD8-Positive Lymphocytes,Suppressor T-Cells, CD8-Positive,CD8 Positive Lymphocytes,CD8 Positive T Lymphocytes,CD8-Positive Lymphocyte,CD8-Positive Suppressor T-Cell,CD8-Positive Suppressor T-Cells,CD8-Positive Suppressor T-Lymphocyte,CD8-Positive Suppressor T-Lymphocytes,CD8-Positive T-Lymphocyte,Cell, T8,Cells, T8,Lymphocyte, CD8-Positive,Lymphocyte, T8,Lymphocytes, CD8-Positive,Lymphocytes, T8,Suppressor T Cells, CD8 Positive,Suppressor T Lymphocytes, CD8 Positive,Suppressor T-Cell, CD8-Positive,Suppressor T-Lymphocyte, CD8-Positive,T-Cell, CD8-Positive Suppressor,T-Cells, CD8-Positive Suppressor,T-Lymphocyte, CD8-Positive,T-Lymphocyte, CD8-Positive Suppressor,T-Lymphocytes, CD8-Positive,T-Lymphocytes, CD8-Positive Suppressor,T8 Cell,T8 Lymphocyte
D019014 fas Receptor A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM. Mutations in the CD95 gene are associated with cases of autoimmune lymphoproliferative syndrome. APO-1 Antigen,Antigens, CD95,CD95 Antigens,Receptors, fas,Tumor Necrosis Factor Receptor Superfamily, Member 6,fas Antigens,fas Receptors,CD95 Antigen,Fas Cell Surface Death Receptor,TNFRSF6 Receptor,fas Antigen,APO 1 Antigen,Receptor, TNFRSF6,Receptor, fas

Related Publications

M Mizuki, and S Tagawa, and M Shibano, and T Hirota, and T Machii, and T Kitani, and M Ohsawa, and K Aozasa, and J Nojima
March 2006, The oncologist,
M Mizuki, and S Tagawa, and M Shibano, and T Hirota, and T Machii, and T Kitani, and M Ohsawa, and K Aozasa, and J Nojima
January 1998, Cancer control : journal of the Moffitt Cancer Center,
M Mizuki, and S Tagawa, and M Shibano, and T Hirota, and T Machii, and T Kitani, and M Ohsawa, and K Aozasa, and J Nojima
January 1998, Ryoikibetsu shokogun shirizu,
M Mizuki, and S Tagawa, and M Shibano, and T Hirota, and T Machii, and T Kitani, and M Ohsawa, and K Aozasa, and J Nojima
November 2007, Presse medicale (Paris, France : 1983),
M Mizuki, and S Tagawa, and M Shibano, and T Hirota, and T Machii, and T Kitani, and M Ohsawa, and K Aozasa, and J Nojima
June 2014, Zhongguo shi yan xue ye xue za zhi,
M Mizuki, and S Tagawa, and M Shibano, and T Hirota, and T Machii, and T Kitani, and M Ohsawa, and K Aozasa, and J Nojima
August 2009, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
M Mizuki, and S Tagawa, and M Shibano, and T Hirota, and T Machii, and T Kitani, and M Ohsawa, and K Aozasa, and J Nojima
October 2007, Current hematologic malignancy reports,
M Mizuki, and S Tagawa, and M Shibano, and T Hirota, and T Machii, and T Kitani, and M Ohsawa, and K Aozasa, and J Nojima
June 1995, Blood,
M Mizuki, and S Tagawa, and M Shibano, and T Hirota, and T Machii, and T Kitani, and M Ohsawa, and K Aozasa, and J Nojima
December 1999, Blood reviews,
M Mizuki, and S Tagawa, and M Shibano, and T Hirota, and T Machii, and T Kitani, and M Ohsawa, and K Aozasa, and J Nojima
July 2003, Seminars in hematology,
Copied contents to your clipboard!